42
Participants
Start Date
August 17, 2025
Primary Completion Date
March 17, 2026
Study Completion Date
March 17, 2026
Adolescent PCOS group receiving oral contraceptives
Participants diagnosed with polycystic ovary syndrome (PCOS) during adolescence will receive a combined oral contraceptive (ethinylestradiol 30 µg + drospirenone 3 mg) once daily for six consecutive months. The intervention aims to regulate menstrual cycles, reduce hyperandrogenic symptoms, and evaluate changes in anxiety and depression scores over time.
Izmir Bakircay University, Izmir
Ege University
OTHER